Eli Lilly's hottest drugs face a quiet new threat

A survey shows a meaningful share of large employers are reconsidering covering GLP-1 drugs for weight loss once 2027 arrives. Eli Lilly shares dipped on June 12 and remain under pressure, down about 2.45% over the past five days. The demand that built Lilly's $1 trillion valuation is now creating friction with employers who pay for the drugs.